In recent years, Colossal Biosciences has taken center stage in the world of biotechnology with its bold claims of resurrecting extinct animals like the woolly mammoth, dire wolf, and even the dodo. Spearheaded by entrepreneur Ben Lamm, the company aims to push the boundaries of genetic engineering and stir excitement in both scientific communities and the general public.
With a market valuation surpassing $10 billion, Colossal Biosciences claims it has made significant strides in its ambitious de-extinction projects. In 2025, the startup revealed the creation of a so-called “woolly mouse,” an organism genetically engineered as a step towards reviving the woolly mammoth. Such endeavors have caught the imagination of the public and media alike, aided by contributions from well-known figures like Paris Hilton and filmmaker Peter Jackson.
However, this excitement is not without controversy. Critics argue that Colossal’s creations are not true resurrected species, but rather scientifically modified versions of current wildlife. For instance, the manipulation of grey wolves’ DNA to recreate something akin to a dire wolf does not meet the scientific definition of de-extinction. These debates are central to understanding whether we can truly revive lost species or are merely fabricating facsimiles.
Renowned scientists express skepticism about Colossal’s ability to achieve genuine de-extinction, suggesting that the biological resurrection of species, currently, remains beyond our scientific reach. Critics caution that such extravagant claims could potentially damage public trust in scientific endeavors by setting unrealistic expectations about the capabilities of genetic engineering.
Beyond the scientific challenges, ethical implications abound. While gene editing holds promise for enriching genetic diversity in endangered species like the red wolf, experts warn against sidestepping traditional conservation methods. Effective conservation still largely depends on habitat preservation and management of invasive species, highlighting that gene editing should complement, rather than replace, these strategies.
Colossal Biosciences stands at a pivotal crossroads of science, ambition, and ethics. While their projects underscore the extraordinary potential of biotechnology, they also serve as a reminder of the vital role that transparency and ethical guidelines play in such groundbreaking research. As we ponder the possibilities of de-extinction, it is essential to approach the future of biotechnology with both hopeful imagination and measured judgment.